SUBSCRIBE
SUBSCRIBE
BioCapital

FDA Stresses Birth Defect Risks with Roche Holding AG and Novartis AG Drugs

May 16, 2008 | 
1 min read

WASHINGTON (Reuters) - U.S. health officials issued an alert on Friday about the risk of first-trimester miscarriages and birth defects from Novartis AG and Roche Holding AG transplant drugs.

Food and Drug Administration (FDA) Novartis
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
April 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3d illustration of hepatitis B viruses i
Drug Development
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
March 28, 2024
 · 
1 min read
 · 
Tyler Patchen